Early Mortality among Patients with Head and Neck Cancer Diagnosed in Thuringia, Germany, between 1996 and 2016—A Population-Based Study

GND
1275151620
ORCID
0000-0002-4822-907X
Affiliation
Department of Otorhinolaryngology, Jena University Hospital, 07747 Jena, Germany;
Kouka, Mussab;
GND
135983371
ORCID
0000-0001-7242-5727
Affiliation
Department of Otorhinolaryngology, Suedharzklinikum Nordhausen, 99734 Nordhausen, Germany;
Buentzel, Jens;
GND
113902123
Affiliation
Department of Otorhinolaryngology, Helios-Klinikum Erfurt, 99089 Erfurt, Germany;
Kaftan, Holger;
GND
122024060
Affiliation
Department of Otorhinolaryngology, SRH Zentralklinikum Suhl, 98527 Suhl, Germany;
Boeger, Daniel;
ORCID
0000-0002-9820-5527
Affiliation
Department of Otorhinolaryngology, SRH Wald-Klinikum Gera, 07548 Gera, Germany;
Mueller, Andreas H.;
GND
141457325
Affiliation
Department of Radiotherapy and Radiation Oncology, Jena University Hospital, 07743 Jena, Germany;
Wittig, Andrea;
GND
172365473
Affiliation
Department of Oromaxillofacial Surgery and Plastic Surgery, Jena University Hospital, 07747 Jena, Germany;
Schultze-Mosgau, Stefan;
GND
1246219492
ORCID
0000-0003-2147-489X
Affiliation
University Tumor Center, Jena University Hospital, 07747 Jena, Germany;
Ernst, Thomas;
GND
1078441464
ORCID
0000-0001-9671-0784
Affiliation
Department of Otorhinolaryngology, Jena University Hospital, 07747 Jena, Germany;
Guntinas-Lichius, Orlando

Simple Summary When we consider the outcome of cancer treatment, we mostly focus on overall survival: studies on early mortality in head and neck cancer (HNC) are sparse. This retrospective population-based study investigated early mortality of HNC and the influence of patients’ tumor and treatment characteristics. All 8288 patients with primary HNC of the German federal state Thuringia from 1996 to 2016 were included. Statistics were performed to identify independent factors for 30-day, 90-day, and 180-day mortality. The 30-, 90-, and 180-day mortality risks were 1.8%, 5.1%, and 9.6%, respectively. Male sex, increasing age, larger tumor size, and distant metastasis, tumors of the cavity of mouth, oropharynx, and hypopharynx had a significantly greater 180-day mortality. Surgery, radiotherapy, and multimodal therapy were associated with decreased 180-day mortality. Typical factors associated with worse overall survival had the most important impact on early mortality in HNC patients in a population-based setting. Abstract Population-based studies on early mortality in head and neck cancer (HNC) are sparse. This retrospective population-based study investigated early mortality of HNC and the influence of patients’ tumor and treatment characteristics. All 8288 patients with primary HNC of the German federal state Thuringia from 1996 to 2016 were included. Univariate and multivariate analysis were performed to identify independent factors for 30-day, 90-day, and 180-day mortality. The 30-, 90-, and 180-day mortality risks were 1.8%, 5.1%, and 9.6%, respectively. In multivariable analysis, male sex (odds ratio (OR) 1.41; 95% confidence interval (CI) 1.08–1.84), increasing age (OR 1.81; CI 1.49–2.19), higher T (T4: OR 3.09; CI 1.96–4.88) and M1 classification (OR 1.97; CI 1.43–2.73), advanced stage (IV: OR 3.97; CI 1.97–8.00), tumors of the cavity of mouth (OR 3.47; CI 1.23–9.75), oropharynx (OR 3.01; CI 1.06–8.51), and hypopharynx (OR 3.27; CI 1.14–9.40) had a significantly greater 180-day mortality. Surgery (OR 0.51; CI 0.36–0.73), radiotherapy (OR 0.37; CI 0.25–0.53), and multimodal therapy (OR 0.10; CI 0.07–0.13) were associated with decreased 180-day mortality. Typical factors associated with worse overall survival had the most important impact on early mortality in a population-based setting.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2022 by the authors.

Use and reproduction:
This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.